Two Quick Videos

As I said in my last post, I'm going to be away from the blog for a little while, but I'll be back before the end of the month. In the meantime, I'm planning to post a couple of things that will automatically be available, so you'll stay in the habit of reading.

This is the first one. 

The website OncLive posted a couple of video commentaries last week. They are short videos discussing some recent research on Follicular Lymphoma.

The first is a video featuring Dr. Vivek Patel of Vanderbilt University Medical Center, who discusses some of the issues with side effects from bispecifics.  He points out that recent clinical trials haven't shown any major (grade 3 or higher) side effects, which would be the most dangerous. There is still an issue with Cytokine Release Syndrome for some patients, but there are protocols in place to recognize and deal with CNS quickly before it becomes a problem. He believes bispecifics are safe and effective and are a good choice for a community-based setting, that is, a regular oncologist's office and treatment room, as opposed to a large hospital.

The second video features Dr. Lorenzo Falchi of Memorial Sloan Kettering in New York, who talks about the findings of the phase 1/2 EPCORE NHL-2 trial, which looks at Epcoritamab in combination with R-Squared (Lenalidomide /Revlimid and Rituxan) in patients with Relapsed/Refractory FL. As Dr. Falchi points out, with 111 patients in the study, there was an Overall Response Rate of 96%, including a Complete Response of 87%. He emphasizes the impressive Minimal Residual Disease rate of 88%, and those patients had a 21 month Progression Free Survival rate of 86%. He says the study says good things about the treatment combination, but also about the ability to use MRD monitoring to help guide decisions about treatment.

They are quick videos, but interesting subject matter. 

I'll set up another post to be published next week, so check back in a bit.